COMP <GO>
XTNT vs SRTS // ALTMAN Z-SCORE & DEBT/EQUITY
Xtant Medical Holdings Inc. (NYSE) VS. Sensus Healthcare Inc. (NASDAQ) • 15-METRIC TALLY: XTNT 7
— SRTS 3
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: SRTS
LAST: $0.29 (+1.54%) • MKT CAP: $40.7M
balance-sheet
0.20
LAST: $2.77 (-1.77%) • MKT CAP: $45.6M
balance-sheet
6.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XTNT VS. SRTS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XTNT | SRTS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.90% | 43.20% | +19.70 | XTNT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | -31.30% | +44.10 | XTNT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.7x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 24.95% | 0.73% | +24.22 | XTNT | /fcf-yield <GO> |
| Operating Margin | 5.40% | -37.50% | +42.90 | XTNT | /operating-margins <GO> |
| Net Profit Margin | 0.00% | -28.10% | +28.10 | XTNT | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | -34.30% | +48.50 | XTNT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.20 | 6.50 | -6.30 | SRTS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | XTNT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.9 | 39.3 | -4.34 | SRTS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.7M | $45.6M | -$4.9M | SRTS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XTNT REV | SRTS REV | XTNT GROSS % | SRTS GROSS % | XTNT FCF | SRTS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $133.9M | $27.5M | 62.9% | 43.2% | $10.2M | $332.0K |
| FY 2024 | $117.3M | $41.8M | 58.2% | 58.4% | -$16.0M | -$1.1M |
| FY 2023 | $91.3M | $24.4M | — | — | -$9.5M | -$2.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XTNT // BETA —
SRTS // BETA —